[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,60,85,111,142,164,198,230,256,282,303,331,357],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053705","screening-for-social-determinants-of-health-sdoh-and-cognitive-function-in-individuals-with-history-of-stroke-100053705",false,"NCT06615973","Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke","Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Adults aged 18 or older.\n* Previous participant in the Natural History of Stroke with an interpretable baseline MRI scan, NIHSS measured at baseline or discharge, and admission diagnosis of ischemic stroke.\n* Fluent in English or Spanish\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this\n\nstudy:\n\n-Modified Rankin Scale (mRS) = 6 at any follow-up (usually up to 90 days) in the Natural History of Stroke study (mRS = 6 indicates the participant is dead).","ALL","18 Years","99 Years",{"count":20,"type":21},450,"ESTIMATED","OBSERVATIONAL","Background:\n\nStroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of maintaining mental functions after a stroke.\n\nObjective:\n\nTo better understand how social and lifestyle factors affect the risk of mental impairment after a stroke.\n\nEligibility:\n\nPeople aged 18 years and older who had a stroke and a brain scan while they were enrolled in NIH Study 01N0007 (Natural History of Stroke Study).\n\nDesign:\n\nParticipants will have 1 study visit, by telephone. The call will last about 45 minutes. Participants will talk about their health since their stroke. They will answer questions about themselves. Topics will include:\n\n* Their race\n* Education\n* Ethnicity\n* Employment\n* Marital status\n* Residence address\n* Recent health history\n* Medical insurance\n\nThey will have tests of their memory, attention, and language skills. They will repeat numbers and words forward and backward.\n\nResearchers will look at the data and imaging scans collected during participant s enrollment in NIH Study 01N0007. This data will include:\n\n* The hospital that first saw the participant at the time of their stroke.\n* The type of imaging that was first used then.\n* The primary diagnosis at admission.\n* Other medical details.",[25,26,27,28],"Stroke","Brain Disease","Vascular Diseases","Cerebrovascular Disorder",[25,30,31,32,33,34],"Social Determinants of Health","Cognition","cerebrovascular health","Magnetic Resonance Imaging (MRI)","vascular health","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":21},"2026-07-16",{"date":43,"type":21},"2027-02-01",{"name":45,"class":46},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":49,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":51,"keywords":52,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":47},"100563423",{"count":20,"type":21},[25,26,27,28],[25,30,31,32,33,34],"2026-07-01",{"date":55,"type":39},"2026-07-02",{"date":57,"type":21},"2026-07-07",{"date":43,"type":21},{"name":45,"class":46},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":47},"100242555","inflammatory-and-infectious-diseases-of-the-nervous-system-100242555","NCT02435810","Inflammatory and Infectious Diseases of the Nervous System","Natural History Study of Inflammatory and Infectious Diseases of the Nervous System","* INCLUSION CRITERIA:\n\nAt the time of enrollment, participants will:\n\n1. Have a known or suspected infection or inflammation of the nervous system or post infection sequelae based on clinical or imaging data provided by the referral facility. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following:\n\n   1. fever with nervous system signs or symptoms (excluding delirium)\n   2. any neurological symptoms accompanied by cerebrospinal fluid (CSF) with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation including IgG index or presence of oligoclonal bands)\n   3. systemic infection or inflammatory disease with neurological involvement\n   4. neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI)\n   5. clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation\n   6. history of infection or inflammatory process of the nervous system\n2. Be willing to participate in the protocol s procedures, unless clinically contraindicated\n3. Be willing to provide informed consent, either directly or via appointed legally authorized representative\n4. Be willing to consent for collection of clinical data or biological samples or their cryopreservation\n5. Be at least 2 years old\n\nINCLUSION CRITERIA FOR PROCESSING OF BIOLOGICAL SAMPLES ONLY:\n\nAt the time of enrollment, participants will:\n\n1. Have a known or suspected infection or inflammation of the nervous system or post infection sequelae based on clinical or imaging data provided by the referral facility. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following:\n\n   1. fever with nervous system signs or symptoms (excluding delirium)\n   2. any neurological symptoms accompanied by cerebrospinal fluid (CSF) with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation including IgG index or presence of oligoclonal bands)\n   3. systemic infection or inflammatory disease with neurological involvement\n   4. neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI)\n   5. clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation\n   6. history of infection or inflammatory process of nervous system\n2. Be willing to provide informed consent, either directly or via appointed legally authorized representative\n3. Be willing to consent for collection of clinical data or biological samples or their cryopreservation\n4. Be at least 2 years old\n\nEXCLUSION CRITERIA:\n\nAt the time of enrollment, participants will:\n\n1. Not have a clinically significant medical condition that, in the best judgment of the investigators, may expose the patient to undue risk of harm or prevent the patient from completing the study (examples include, but are not limited to, ischemic cardiomyopathy, clotting disorder, brittle diabetes)\n2. Not have an acute or unstable medical condition that, in the best judgement of the investigator, would be difficult to handle at the NIH Clinical Center\n3. Not have a clearly-established diagnosis of well-characterized disease entity with validated treatment algorithms for which proposed resource investment, in the opinion of the investigators, would not contribute to further advancement of knowledge\n\nEXCLUSION CRITERIA FOR PROCESSING OF BIOLOGICAL SAMPLES ONLY:\n\nAt the time of enrollment, participants will not have:\n\n1\\. A clearly-established diagnosis of well-characterized disease entity with validated treatment algorithms for which proposed resource investment, in the opinion of the investigators, would not contribute to further advancement of knowledge\n\nINCLUSION CRITERIA FOR FAMILY MEMBERS:\n\n1. Have a family member enrolled on 15-N-0125\n2. Be at least 2 years old\n3. Be able to provide informed consent and comply with study procedures\n\nEXCLUSION CRITERIA FOR FAMILY MEMBERS:\n\n1\\. Not willing to consent for collection of biological samples or their cryopreservation","2 Years","110 Years",{"count":70,"type":21},1000,"Background:\n\n\\- Inflammation is how the body reacts to infection or injury. Infections or inflammation in the brain and nerves can be serious. There aren t always good tests to detect this. Researchers want to learn more about how diseases affect the brain and nerves to develop better tests and treatments.\n\nObjective:\n\n\\- To learn more about how inflammation and infections hurt the brain and nervous system.\n\nEligibility:\n\n\\- People at least 2 years old with a diagnosis or suspected diagnosis of nervous system infection or inflammation.\n\nDesign:\n\n* For some participants, a clinician outside of NIH will collect blood, tissue, and other samples. These will be sent to NIH and analyzed.\n* Other participants will have several visits to NIH. Children may not have all these tests.\n* Participants will have:\n* Medical history.\n* Physical and neurological exam.\n* Blood and urine samples collected.\n* Saliva collected. They will chew on a piece of sterile cotton for one minute.\n* Magnetic resonance imaging (MRI) scan. The scanner is a metal cylinder in a strong magnetic field. Participants will lie on a table that slides in and out of the cylinder. Participants will get a contrast agent through an intravenous (IV) catheter during the MRI. A needle will be used to guide a thin plastic tube (catheter) into an arm vein.\n* Lumbar puncture. Skin will be numbed and a needle will be inserted into the space between the bones in the back. Fluid will be removed.\n* Some participants may have optional study procedures. These may include eye tests, memory and thinking testing, tests with electrodes on the head, or skin biopsy.",[26],[74,75,76],"Neuroinflammation","Infections","Natural History","2026-06-17",{"date":79,"type":39},"2026-06-18",{"date":81,"type":39},"2015-05-06",{"date":83,"type":21},"2026-11-29",{"name":45,"class":46},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":4,"leadSponsor":109,"locationsCount":110},"100058931","natural-history-of-stroke-cause-and-development-100058931","NCT00009243","Natural History of Stroke: Cause and Development","Evaluation, Pathogenesis, and Treatment of Patients With or at Risk for Cerebrovascular Disease (A Natural History\u002FDisease Pathogenesis Protocol)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Aged \\>=18\n2. Presented to participating study site (ED, ICU, or inpatient unit) with or at risk of acute stroke, TIA, or other disturbances of cerebrovascular circulation\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Subjects with contraindication to MRI scanning will be excluded from any testing which involves the use of MRI. The contraindications include subjects with the following devices or conditions:\n\n   * Central nervous system aneurysm clips\n   * Implanted neural stimulator\n   * Implanted cardiac pacemaker or defibrillator\n   * Cochlear implant\n   * Ocular foreign body (e.g. metal shavings)\n   * Insulin pump\n   * Metal shrapnel or bullet\n   * Any implanted device that is incompatible with MRI\n\n   Subjects with a condition precluding entry in the scanner (e.g. morbid obesity, Claustrophobia, etc.) will not be included in the MRI portion of this study.\n2. Pregnancy","120 Years",{"count":94,"type":21},4000,"The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.\n\nPatients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.\n\nThe study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:\n\n* Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests.\n* Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm.\n* Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain.\n* Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.\n* Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck.\n* Echocardiogram-sound waves are used to image the heart and evaluate heart function.\n\nPatients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and\u002For 12 months, when some of these tests may be repeated to assess changes over time",[26,97,98,28,27],"Ischemic Attack, Transient","Cerebrovascular Accident",[25,76,100,101,102,103],"MRI (Magnetic Resonance Imaging)","Magnetic Resonance Imaging","Acute Stroke","TIA","2026-06-13",{"date":106,"type":39},"2026-06-16",{"date":108,"type":39},"2001-01-26",{"name":45,"class":46},3,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":47},"100384501","brain-connections-for-arm-movement-after-stroke-100384501","NCT04286516","Brain Connections for Arm Movement After Stroke","Brain Areas That Control Reaching Movements After Stroke: Task-relevant Connectivity and Movement-synchronized Brain Stimulation","CAM","Inclusion Criteria:\n\nInclusion Criteria (control participants):\n\n* Be 45-90 years of age\n* Have adequate language and neurocognitive function to participate in training and testing\n* Be medically stable to participate in the study\n* Be English speaking\n\nInclusion Criteria (participants with stroke):\n\n* Be 45-90 years of age\n* Clinically defined, unilateral, hemiparetic stroke with radiologic exclusion of other possible diagnosis\n* Stroke onset at least 6 months before enrollment\n* Subcortical stroke (ex: internal capsule, deep white matter of posterior frontal lobe)\n* Present with mild to moderate arm dysfunction\n* Be medically stable to participate in the study\n* Be English speaking\n\nExclusion Criteria:\n\n(for both groups)\n\n* Unable to give informed consent\n* Have a serious complicating medical illness that would preclude participation\n* Contractures or orthopedic problems limiting range of joint motion in the potential study arm or other impairments that would interfere with the study activities\n* Visual loss such that the subject would not be able to see the test patterns on the robot computer monitor\n* Unable to comply with requirements of the study\n* Enrollment in another greater-than-minimal risk study\n* Presence of medical condition or implant that prevents safe administration of TMS or MRI\n* Pregnancy",true,"45 Years","90 Years",{"count":123,"type":21},76,"INTERVENTIONAL",[126],"NA","The purpose of this study is to use Transcranial Magnetic Stimulation (TMS) while subjects are making reaching movements in a robotic arm device in order to discover how different brain areas control movement before and after stroke and when these brain areas are most sensitive to TMS.",[25,26,129,130,131],"Central Nervous System Diseases","Nervous System Diseases","Cardiovascular Diseases","2026-05-28",{"date":134,"type":39},"2026-06-02",{"date":136,"type":39},"2020-01-10",{"date":138,"type":21},"2027-06-01",{"name":140,"class":141},"VA Office of Research and Development","FED",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":124,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100539440","deep-brain-stimulation-motor-ventral-thalamus-vopvim-for-restoration-of-speech-and-upper-limb-function-in-people-with-subcortical-stroke-100539440","NCT06303869","Deep Brain Stimulation Motor Ventral Thalamus (VOP\u002FVIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke","Inclusion Criteria:\n\n1. Participants must have suffered a single, ischemic, or hemorrhagic stroke more than 6 months before the time of enrollment with dysarthria as a result.\n2. Participants must be between the ages of 18 and 75 years old. (Participants outside this age range may be at an increased medical risk and have an increased risk of fatigue during testing).\n3. English speaker.\n4. Participant must score ≤ 80% in at least 4 categories of the perceptual speech assessment (speech intelligibility, listener effort, speech naturalness, articulatory precision, speech rate, overall voice quality, and\u002For overall speech severity). OR ≤ 80% in at least 3 categories of the perceptual speech assessment AND ≤ 27 on the Communicative Participation Item Bank.\n\nExclusion Criteria:\n\n1. Patients who refuse participation in the study.\n2. Patients with gross anatomical variances in MR imaging or cerebral vascular accidents involving thalamic and cerebellar areas.\n3. Patients with no clinical condition to undergo DBS implantation or highly dependent on anticoagulation therapy.\n4. Patients who cannot undergo pre-operative MRIs or could not complete the pre-operative assessments.\n5. Participants must not have any serious disease or disorder (ex. neurological condition other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) or cognitive impairments that could affect their ability to participate in this study.\n6. Female participants of child-bearing age must not be pregnant, planning to become pregnant for the next 9 months, or breast feeding.\n7. Participants must not be receiving anticoagulants.\n8. Severe claustrophobia.\n9. Participants must not be on anti-spasticity or anti-epileptic medications for the duration of the study.\n10. Participants who have been deemed inappropriate for participation based upon results from the Brief Symptoms Inventory (BSI-18) and discussions with the Principal Investigator and a study physician\n11. Evaluation to sign consent form score \\<12.\n12. MRI contraindications (excluding subjects who are pregnant, who have metal in any portion of their body, have medical complications, cardiac pacemaker, cochlear implant, aneurysm clip, certain IUDs, or known problems of claustrophobia).\n13. Medications with common cognitive side-effects.\n14. Bleeding disorders or platelet dysfunction (e.g., from regular aspirin usage).\n15. Patients must not have any lesions in the lower motoneuron causing flaccid dysarthria.","75 Years",{"count":150,"type":21},10,[126],"The goal of this study is to verify whether the use of deep brain stimulation can improve motor function of the hand and arm and speech abilities for people following a stroke. Participants will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neuro-rehabilitation programs to restore speech and upper limb motor functions in people with subcortical strokes, thereby increasing independence and quality of life.",[25,26,129,130,131],"2026-05-05",{"date":156,"type":39},"2026-05-08",{"date":158,"type":39},"2025-06-20",{"date":160,"type":21},"2029-12",{"name":162,"class":163},"Jorge Gonzalez-Martinez","OTHER",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":180,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":47},"100607383","study-of-axial-and-cognitive-symptoms-and-biomarkers-of-neurodegeneration-in-brain-first-and-body-first-pd-100607383","NCT07187843","Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD","Study of the Progression of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Patients With Parkinson's Disease Divided Into Brain-first and Body-first Phenotypes","BRABOAXPD","Inclusion Criteria:\n\n* Patients diagnosed with PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease divided into brain-first and body-first phenotypes, based on the presence or absence of a REM sleep behavior disorder diagnosed using ambulatory polysomnography methods according to the criteria of the International Classification of Sleep Disorders (ICSD-3) criteria and on data from SPECT with DATSCAN and myocardial innervation scintigraphy \\[123I-MIBG\\].\n* Free and informed consent expressed by the participant.\n* At least 18 years of age.\n\nExclusion Criteria:\n\n* Inability to express free and informed consent.\n* Patient with a doubtful diagnosis.\n* Participant under 18 years of age.",{"count":173,"type":21},150,"This observational study aims to systematically characterize a cohort of patients with early-stage Parkinson's disease (PD) attending the Movement Disorders Center of AUSL-IRCCS Reggio Emilia, Italy. PD is the second most common neurodegenerative disorder, affecting about 1% of individuals over 60 years of age. The project will explore clinical and biological differences between the recently proposed \"Brain-First\" and \"Body-First\" phenotypes of PD. Patients will undergo detailed clinical evaluation, neuroimaging, and biomarker assessments (including neurodegeneration and neuroinflammation markers). Particular attention will be given to the progression of axial and cognitive symptoms, which represent major contributors to disability.\n\nFindings from this study are expected to improve early patient stratification, clarify disease mechanisms, and support the development of precision medicine strategies and future disease-modifying therapies.",[176,177,26,178,179],"Parkinson Disease","Parkinsonian Disorders","Basal Ganglia Diseases","Synucleinopathies",[181,130,182,183,184,185,186,187],"Neurodegenerative Diseases","Movement Disorders","biomarker","neuroinflammation","brain-first","body-first","axial symptoms","2026-04-22",{"date":190,"type":39},"2026-04-23",{"date":192,"type":39},"2024-09-04",{"date":194,"type":21},"2031-05",{"name":196,"class":197},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":208,"conditions":209,"keywords":215,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":47},"100612468","prospective-evaluation-of-atrial-fibrillation-related-stroke-patients-in-rehabilitation-program-pearl-an-observational-cohort-study-100612468","NCT07253974","Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study","Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study. TARGET: Health Virtual Twins for the Personalised Management of Stroke Related to Atrial Fibrillation\".","PEARL","Inclusion Criteria:\\> 18 a, first-ever intracerebral ischemic stroke\n\n\\-\n\nExclusion Criteria:\n\n* intracranial haemorrhage, symptomatic hemorrhagic transformation, new infarcts after the initial stroke or other neurological or psychiatric conditions.",{"count":207,"type":21},213,"The goal of this observational study is to determine if rehabilitation program intensity impacts functional recovery and specific needs in adult ischemic stroke patients who require inpatient rehabilitation. The main questions it aims to answer are:\n\nDo patients with stroke of Atrial-related subtypes (AFRS) have distinct rehabilitation needs and functional outcomes compared to non-AFRS patients? Does higher-intensity inpatient rehabilitation (3-5 sessions\u002Fday) result in better functional recovery at six months (measured by the Barthel Index) than moderate-intensity programs (1 session\u002Fday)? The study is non-invasive, does not interfere with usual care. The investigators' ultimate goal is to enhance the understanding of recovery after following different rehabilitation usual programs.",[210,211,26,212,213,214],"STROKE","Rehabilitation Outcome","Cardiovascular Disease Acute","Hemiplegia and\u002For Hemiparesis Following Stroke","Disability Physical",[216,217,218,219,220],"functional outcomes","stroke","disability","rehabilitation","high intensity rehabilitation program","2025-12-11",{"date":223,"type":39},"2025-12-15",{"date":225,"type":39},"2024-11-11",{"date":227,"type":21},"2027-12-01",{"name":229,"class":163},"Parc de Salut Mar",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":119,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":124,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":47},"100597273","long-term-brain-stimulation-of-the-motor-ventral-thalamus-vopvim-to-improve-motor-function-100597273","NCT07056348","Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP\u002FVIM) to Improve Motor Function","Chronic Stimulation of the Motor Ventral Thalamus (VOP\u002FVIM) for Motor Control in Humans","Inclusion Criteria:\n\n* Movement disorder patients ≥18 years of age and \\\u003C 80 years of age, who will be implanted with DBS for treatment of motor symptoms.\n* Subject has provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures.\n\nExclusion Criteria:\n\n* History of seizure disorders\n* Vasovagal response history and loss of consciousness history\n* Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator would impact participation in the study.\n* Any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, neurological conditions other than current movement disorder) or cognitive impairments that could impair ability to participate in this study.\n* Females who are pregnant or breastfeeding.","80 Years",{"count":239,"type":21},60,[126],"This study aims to recruit patients already implanted with Deep Brain Stimulation (DBS) for movement disorders to complete tasks assessing parameters of motor output, speech, and swallowing functions, both with and without stimulation. DBS parameters would be adjusted prior to motor testing. Patients would then participate in multiple sessions performing contralateral upper extremity movement tasks measuring movement speed, grip strength, and strength modulation, facial movement, swallowing, and speech tasks.",[243,25,26,244,245,246,247],"Traumatic Brain Injury","Movement Disorders (Incl Parkinsonism)","Central Nervous System Disease","Essential Tremor, Movement Disorders","Essential Tremor of Voice","2025-12-08",{"date":250,"type":39},"2025-12-16",{"date":252,"type":39},"2022-05-10",{"date":254,"type":21},"2030-12-31",{"name":162,"class":163},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":124,"phases":266,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":47},"100501707","phase-4-sgc-stimulation-perioperative-vascular-reactivity-and-organ-injury-in-cardiac-surgery-100501707","NCT05812755","SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery","The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery","SOLSTICE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy\n\nExclusion Criteria:\n\n1. Intolerance to vericiguat\n2. Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors\n3. Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test\n4. Renal replacement therapy within 30 days prior to screening\n5. Estimated glomerular filtration rate \\\u003C15 ml\u002Fmin per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening\n6. Systolic blood pressure less than 120 mmHg at the time of screening\n7. Prior kidney transplantation\n8. History of significant liver dysfunction (defined as Child-Pugh class C)\n9. Surgery scheduled to be performed with circulatory arrest\n10. Surgery scheduled to correct a major congenital heart defect\n11. Extracorporeal membrane oxygenation (ECMO) prior to surgery\n12. Active systemic infection or surgery for infectious endocarditis\n13. Ventricular assist device or intraaortic balloon pump support prior to surgery\n14. Prisoners",{"count":265,"type":21},170,[267],"PHASE4","The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are:\n\n1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo?\n2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo?\n\nParticipants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury.\n\nThis will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.",[270,27,271,26,272],"Endothelial Dysfunction","Kidney Injury","Vascular Inflammation","2025-07-02",{"date":275,"type":39},"2025-07-08",{"date":277,"type":39},"2023-05-19",{"date":279,"type":21},"2027-11",{"name":281,"class":163},"Vanderbilt University Medical Center",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":119,"sex":16,"minAge":288,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":124,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":47},"100391962","clinical-translation-of-a-novel-brain-pet-insert-for-simultaneous-petmr-100391962","NCT04383808","Clinical Translation of a Novel Brain PET Insert for Simultaneous PET\u002FMR","Inclusion Criteria:\n\n1. Whole body radiation dose within the last year of less than 5000 mrem\n2. Subjects intended for injected tracer studies (not associated with another study) must be willing\u002Fable to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved\n3. Subjects will be at least 21 years of age\n4. Subject provides written informed consent\n5. Subject is deemed healthy by the PI by via self-reported questionnaire\n\nExclusion Criteria:\n\n1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents\n2. Participant has a history of or current diagnosis of cancer\n3. Participant is pregnant or nursing\n4. Metallic implants (contraindicated for MRI)","21 Years",{"count":290,"type":21},40,[126],"The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET\u002FMR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET\u002FMRI system using a common radiopharmaceutical.",[26],"2025-04-03",{"date":296,"type":39},"2025-04-06",{"date":298,"type":39},"2025-04-01",{"date":300,"type":21},"2028-03-31",{"name":302,"class":163},"Stanford University",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":119,"sex":16,"minAge":17,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":124,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":329,"locationsCount":47},"100570266","monitoring-of-brain-metabolites-using-proton-and-deuterium-mr-techniques-100570266","NCT06705010","Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques","Non-Invasive Monitoring of Brain Metabolites Using Novel and Adapted Proton and Deuterium MR Techniques","SIGNATURES2023","General Inclusion Criteria (applicable to all groups):\n\n1. Signed informed consent by the participant.\n2. Ability to lie still in the MR scanner for at least one hour.\n3. No current or lifetime history of drug or alcohol abuse.\n4. No medications that interfere with cognition.\n5. Normal or corrected-to-normal vision.\n\nDisease-Specific Inclusion Criteria:\n\nI. Type 2 Diabetes Patients group (PG-IV-2H-DM):\n\n* Diagnosis of Type 2 diabetes according to the ADA classification.\n* Treatment with lifestyle modification and\u002For non-insulin agents.\n\nII. High-Grade Carotid Stenosis Patient Group (PG-IV-1H-HGCS):\n\n* ≥50% stenosis of the carotid artery.\n\nIII. Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) Patients (PG-IV-2H-AD\u002FMCI):\n\n* Diagnosis of Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD).\n* Age range between 60-80 years.\n* Fluent in German.\n* Normal or corrected-to-normal vision and hearing.\n* Ability to understand the research and provide informed consent.\n\nExclusion Criteria:\n\n1. Under 18 years of age.\n2. Claustrophobia.\n3. Pregnancy or current state of lactation.\n4. Active implants (e.g., pacemakers, neuro-stimulators).\n5. Passive ferromagnetic implants.\n6. Passive non-ferromagnetic metallic implants \\> 4 cm in a region covered by the active radio frequency (RF) coils.\n7. Large tattoos inside a region covered by the active RF coils.\n8. Known or suspected non-compliance.\n9. Underweight \\\u003C30 kg body weight.\n10. Body mass index (BMI) \\> 30.\n11. Overweight \\>135 kg\n12. Persons with extreme big head circumference or extreme astigmatism, which cannot be corrected by MR-compatible eyeglasses.\n13. Persons not able to understand the informed consent form.\n14. Not agreeing with the institute's policy to inform the subject on incidental findings discovered during the examination.\n15. Visual and auditory acuity impairing neuropsychological testing (if relevant).\n16. Diabetes or glucose intolerance according to WHO recommendations (excluded in the diabetes patient group).\n17. Evidence of overt heart or renal disease.\n18. Evidence of gastrointestinal tract disease.\n19. Cognitive impairment (Mini-mental state examination score \\\u003C26\u002F30, CDR score \\>0, memory complaints) (excluding AD, MCI groups).\n20. Smoking.\n21. Current or life-time drug or alcohol abuse\n22. Untreated dyslipidemia, hypertension, or thyroid disease.\n23. Antidepressant medications with anticholinergic properties.\n24. Regular use of narcotic agents more than two doses per week within 4 weeks of screening.\n25. Antiparkinsonian medications used within 4 weeks of screening.\n26. Enrollment in any investigational drug studies within 4 weeks of screening.\n27. Immunomodulating or oncological treatment.\n28. Cardiac implantable electronic devices (CIED) such as pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices.\n29. Metallic intraocular foreign bodies: patients who have ever welded without eye protection or had facial injuries involving metal must have an orbit x-ray reviewed by a radiologist before MRI.\n30. Implantable neurostimulation systems.\n31. Cochlear implants\u002Fear implants.\n32. Drug infusion pumps (insulin delivery, analgesic drugs, or chemotherapy pumps).\n33. Catheters with metallic components (e.g., Swan-Ganz catheter).\n34. Metallic fragments (e.g., bullets, shotgun pellets, shrapnel).\n35. Cerebral artery aneurysm clips.\n36. Magnetic dental implants.\n37. Tissue expanders.\n38. Artificial limbs.\n39. Non-removable hearing aids.\n40. Non-removable piercings.\n41. Implantable cardiocerter defibrillators\n42. Cardiac resynchronization therapy devices\n43. Fever (temperature \\> 37.5°C measured prior to MRI).\n44. Volunteers taking amphetamines or sedatives","130 Years",{"count":313,"type":21},140,[126],"MR pulse for whole brain optimal Deuterium (2H) Metabolic Imaging and EPSI (echo planar spectroscopic imaging) based SLOW-edited 1H-MRSI will be developed and optimized for use at an UHF scanner at 7 Tesla. The study has 4 phases.\n\nPhase I: The 2H and 1H MRSI sequences are developed and optimized in vitro (phantoms)\n\nPhase II: Sequences are applied in vivo in healthy volunteers and further optimized\n\nPhase III: Optimal 2H 1H pulse sequences are applied in 4 cohorts of healthy volunteers, to study the effect of aging with whole brain 2H and 1H MRSI.\n\nPhase IV: application of the sequences in 4 patient groups with different diseases: Alzheimer's diseases (AD) patients, diabetes mellitus type II (DM) patients, mild cognitive impaired (MCI) patients, and high grade carotid stenosis patients (HGCS).\n\nThe ultimate aim is to create for individual patient specific 3dimensional spatial resolved z-score maps (similar to FDG-PET) based on the healthy control data of phase III of the trial.",[317,318,319,320,321,322,26],"Aging","Brain Metabolic Disorder","Carotid Stenosis","Alzheimer Disease","Diabetes Type 2","Mild Cognitive Impairment","NOT_YET_RECRUITING","2025-03-24",{"date":326,"type":39},"2025-03-25",{"date":298,"type":21},{"date":300,"type":21},{"name":330,"class":163},"Insel Gruppe AG, University Hospital Bern",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":337,"targetDuration":4,"studyType":124,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100581502","18f-dpa-714-petmr-in-dysfunctional-brain-diseases-100581502","NCT06851143","18F-DPA-714 PET\u002FMR in Dysfunctional Brain Diseases","Inclusion Criteria:\n\n* Dysfunctional disorders diagnosed according to the guidelines include: cognitive disorders, movement disorders, disorders of consciousness-like disorders, and autoimmune encephalitis. Signing the PET\u002FMR informed consent form to volunteer for this study\n\nExclusion Criteria:\n\n* Minors, pregnant women, nursing mothers, those with severe liver or kidney insufficiency, history of allergy to contrast media or other drugs. Diagnosis of viral encephalitis, acute myelitis, idiopathic epilepsy, antibody-negative AIE; diagnosis of any major disease; history of alcohol or drug abuse\u002Fdependence; history of cardiorespiratory disease, oncology, haematological disorders, poorly controlled chronic diseases; contraindications to PET\u002FMR examination. History of head trauma, history of surgery. History of other neurological disorders.",{"count":338,"type":21},65,[126],"This is a diagnostic pilot study that recruited 25 normal volunteers and 40 patients with dysfunctional brain diseases and performed 18F-DPA-714 PET\u002FMR imaging to evaluate the correlation between the multimodal imaging features of dysfunctional brain diseases, to explore the potential pathological mechanisms of neuroimmune activation, and to further analyse the value of PET\u002FMR-based multimodal imaging in the diagnosis and differential diagnosis of dysfunctional brain diseases. and further analyse the diagnostic and differential diagnostic value of PET\u002FMR-based multimodal imaging in dysfunctional brain diseases.",[26],[343,344,345,346,347],"18F-DPA-714 PET\u002FMR","cognitive impairment","dyskinesia","Disorders of consciousness","Autoimmune encephalitis","2025-02-26",{"date":350,"type":39},"2025-02-28",{"date":352,"type":21},"2025-03-01",{"date":354,"type":21},"2027-12-31",{"name":356,"class":163},"Xijing Hospital",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":363,"targetDuration":4,"studyType":124,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":47},"100539279","a-prospective-experimental-multicenter-open-label-randomized-controlled-trial-of-3-month-dual-antiplatelet-therapy-followed-by-ticagrelor-versus-6-month-dual-antiplatelet-therapy-followed-by-ticagrelor-after-implanting-bridge-100539279","NCT06301776","A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge","Inclusion Criteria:\n\n* Patients who are suitable for Bridge implantation\n* Symptomatic vertebral artery stenosis with a history of posterior circulation-related ischaemic stroke or TIA despite the use of at least one antithrombotic medications and intervention for risk factors\n* Responsible vertebral artery stenosis (≥70% stenosis, measured by the NASCET method ) confirmed by DSA imaging\n* The patient and\u002For his\u002Fher authorised person understands the purpose of the study, agrees to participate in the study and signs the informed consent form\n\nExclusion Criteria:\n\n* mRS≥3\n* Presence of tandem stenotic lesions in the target lesion areaor combined basilar artery stenosis Presence of ≥2 stenotic cerebrovascular lesions requiring concurrent intervention The presence of severe tortuosity or calcification of the target vessel, or the presence of extensive abnormal vascular structural variants that are difficult for catheters or stents to pass or cannot be implanted\n* Lesions or stenosis that is too large and beyond the specification of the stent\n* Non-atherosclerotic stenosis such as atrial fibrillation, vasculitis stenosis, arterial entrapment, smoky disease, active phase of arteritis, or unknown cause\n* Contraindication to heparin, aspirin, tegretol, clopidogrel, or other antiplatelet drugs, and those who cannot tolerate anticoagulant and antiplatelet drug therapy\n* Have had intracranial haemorrhage within 3 months\n* Had a myocardial infarction or large cerebral infarction within 2 weeks\n* Accompanied by other intracranial disease such as aneurysm, arteriovenous malformation, intracranial tumour, intracranial infection, etc\n* Presence of active bleeding or extremely dangerous risk of haemorrhage (e.g. active peptic ulcer disease, gastrointestinal lesions with bleeding risk, malignant tumours with bleeding risk, etc.)\n* Severe cardiac, hepatic, splenic, pulmonary, or renal impairment, or allergy or intolerance to contrast media, rapamycin (Rapamycin) and its derivatives, cobalt-based alloys, or polylactic acid",{"count":364,"type":21},560,[126],"To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy.",[26,368],"Vertebral Artery Stenosis","2024-03-04",{"date":371,"type":39},"2024-03-08",{"date":373,"type":39},"2023-12-05",{"date":375,"type":21},"2026-06-30",{"name":377,"class":163},"The Fourth Affiliated Hospital of China Medical University"]